Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313492721> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4313492721 endingPage "363" @default.
- W4313492721 startingPage "350" @default.
- W4313492721 abstract "The extended patent term or exclusivity period from pharmaceuticals’ approval date is limited to 14 years in the US or 15 years in the EU. However there are no such restrictions in Korea, so the market exclusivity can be excessively extended. Therefore, the status of extension of patent term in Korea was analyzed and the patent term from the product’s approval date in Korea, the US, Japan, the UK, France, and Germany were compared. For that, the following information from NEDRUG or KIPRIS were collected and analyzed: the filing date of the patent, whether the patent term has been extended, the expiration date of the patent term, approval date, the products’ name, and representative claims. Alecensa, Xalkori, Biktarvy, and Champix were selected for the comparison. Among 597 patents in Korea, 90.1% (538) were extended and 17.1% (102) of patents exceeded 14 years from the approval date. There were 81 and 60 products that have patents whose term exceeds 14 and 15 years from the approval date, respectively. In the comparative cases of 4 products, the patent term from products’ approval date in Korea is longer than 14 or 15 years, whereas the US, the UK, France, and Germany comply with the regulated limitation. The excessive patent protection delays the market entry of lower-cost generics and leads to an increase in financial burden on healthcare cost. To address such problems, a proper limitation on the extension of the patent term from the product’s approval date needs to be established." @default.
- W4313492721 created "2023-01-06" @default.
- W4313492721 creator A5010426809 @default.
- W4313492721 creator A5047693100 @default.
- W4313492721 creator A5058355869 @default.
- W4313492721 creator A5083435472 @default.
- W4313492721 date "2022-12-30" @default.
- W4313492721 modified "2023-10-16" @default.
- W4313492721 title "Comparative Study on the Extended Patent Term to Restrain Patent Owners from Obtaining the Excessive Market Exclusivity Regarding Pharmaceuticals in Korea, the US, Japan, the UK, France, and Germany" @default.
- W4313492721 doi "https://doi.org/10.17480/psk.2022.66.6.350" @default.
- W4313492721 hasPublicationYear "2022" @default.
- W4313492721 type Work @default.
- W4313492721 citedByCount "0" @default.
- W4313492721 crossrefType "journal-article" @default.
- W4313492721 hasAuthorship W4313492721A5010426809 @default.
- W4313492721 hasAuthorship W4313492721A5047693100 @default.
- W4313492721 hasAuthorship W4313492721A5058355869 @default.
- W4313492721 hasAuthorship W4313492721A5083435472 @default.
- W4313492721 hasConcept C121332964 @default.
- W4313492721 hasConcept C144133560 @default.
- W4313492721 hasConcept C155202549 @default.
- W4313492721 hasConcept C162118730 @default.
- W4313492721 hasConcept C185592680 @default.
- W4313492721 hasConcept C2524010 @default.
- W4313492721 hasConcept C2780584464 @default.
- W4313492721 hasConcept C2985089533 @default.
- W4313492721 hasConcept C31903555 @default.
- W4313492721 hasConcept C33923547 @default.
- W4313492721 hasConcept C61797465 @default.
- W4313492721 hasConcept C62520636 @default.
- W4313492721 hasConcept C90673727 @default.
- W4313492721 hasConceptScore W4313492721C121332964 @default.
- W4313492721 hasConceptScore W4313492721C144133560 @default.
- W4313492721 hasConceptScore W4313492721C155202549 @default.
- W4313492721 hasConceptScore W4313492721C162118730 @default.
- W4313492721 hasConceptScore W4313492721C185592680 @default.
- W4313492721 hasConceptScore W4313492721C2524010 @default.
- W4313492721 hasConceptScore W4313492721C2780584464 @default.
- W4313492721 hasConceptScore W4313492721C2985089533 @default.
- W4313492721 hasConceptScore W4313492721C31903555 @default.
- W4313492721 hasConceptScore W4313492721C33923547 @default.
- W4313492721 hasConceptScore W4313492721C61797465 @default.
- W4313492721 hasConceptScore W4313492721C62520636 @default.
- W4313492721 hasConceptScore W4313492721C90673727 @default.
- W4313492721 hasIssue "6" @default.
- W4313492721 hasLocation W43134927211 @default.
- W4313492721 hasOpenAccess W4313492721 @default.
- W4313492721 hasPrimaryLocation W43134927211 @default.
- W4313492721 hasRelatedWork W1855069724 @default.
- W4313492721 hasRelatedWork W2174438959 @default.
- W4313492721 hasRelatedWork W2372135159 @default.
- W4313492721 hasRelatedWork W2384675785 @default.
- W4313492721 hasRelatedWork W281246900 @default.
- W4313492721 hasRelatedWork W2955325128 @default.
- W4313492721 hasRelatedWork W2994190837 @default.
- W4313492721 hasRelatedWork W3022942420 @default.
- W4313492721 hasRelatedWork W3138148381 @default.
- W4313492721 hasRelatedWork W4315780250 @default.
- W4313492721 hasVolume "66" @default.
- W4313492721 isParatext "false" @default.
- W4313492721 isRetracted "false" @default.
- W4313492721 workType "article" @default.